Introduction
The prevalence of thyroid nodules in the general population is high and is reported to be between 8 and 65% [1] . Due to the significant advances in imaging technology and the increased use of neck imaging, detection of unsuspected thyroid nodules, known as incidentalomas, is on the rise. 18 
F-FDG (2-[
18 F]-fluoro-2-deoxy-D -glucose) PET/CT (positron emission tomography/computed tomography) has been increasingly used for assessment of various malignancies and plays an integral role in cancer management. 18 F-FDG is a glucose analogue and the mechanism of 18 F-FDG uptake and detection of tumours is based on the higher glycolytic metabolism and the higher expression of membrane glucose transporter (GLUT) proteins in the malignant tissue [2] . Incidental diffuse and focal thyroid uptake is often seen on 18 F-FDG PET/CT study. Diffuse uptake in the thyroid has been reported in approximately 0.6-3.3% of the 18 F-FDG PET studies and is often due to a benign aetiology [3] . The prevalence of focal uptake within the thyroid (incidentaloma) on 18 F-FDG PET has been noted to range from 0.2 to 10.1% in various studies. This is clinically more significant due to its high risk of malignancy in these lesions and the reported risk of malignancy is varied (8-64%) [4] . Malignancy identified within the thyroid incidentaloma on 18 F-FDG PET has been noted to be of a higher grade/aggressive subtype [5] , requiring prompt evaluation by the clinician. This may create a management dilemma for the referring clinicians [6] .
The maximum standardised uptake value (SUV max ) assessed by 18 F-FDG PET is a semi-quantitative measure of glucose metabolism, which is useful in the estimation of tumour grade or aggressiveness and as a marker in assessment of response to treatment. It is defined as the maximum uptake in the lesion scaled by the administered activity and patient weight or height [7] . Some studies claim a beneficial role of the SUV max in differentiating benign from malignant thyroid pathology, but this has not been replicated in other studies and therefore remains controversial [8, 9] .
The aim of this study was to assess the pathological nature of the focal thyroid incidentalomas detected on 18 F-FDG PET and the role of the SUV max in differentiation of benign from malignant thyroid pathology in these patients.
Materials and Methods
This was a retrospective study reviewing 18 F-FDG PET or PET/ CT scan reports of 29,300 studies performed in the nuclear medicine department at our institution between January 1999 and December 2013 for various oncological and non-oncological indications. Institutional review board approval was obtained for the study.
The search criteria 'uptake in the thyroid' was applied to these scan reports, which provided 147 results as having incidental focal tracer uptake in the thyroid. Patients with an established diagnosis of a malignant primary thyroid neoplasm were excluded from the analysis. Data including age, sex, primary malignancy site, indication for the PET study and the SUV max of the focal thyroid uptake were recorded.
PET/CT imaging was performed 60 min after injection of 18 F-FDG (5 MBq/kg of body weight). Standard patient preparation prior to the study included a fasting period of at least 4-6 h and a serum glucose level <7 mmol/l (120 mg/dl) before 18 F-FDG administration.
The PET scan report in patients with a focal uptake in the thyroid gland recommended further evaluation of the uptake with ultrasonography (USG) with and without fine-needle aspiration (FNA) and where appropriate referral to the head and neck, endocrinology or endocrine surgery teams for further management. The final diagnosis for the focal thyroid incidentalomas was made by USG of the neck, FNA cytology (FNAC) or histopathology of the surgically resected specimen, where available. The prevalence of thyroid incidentalomas on 18 F-FDG PET or PET/CT and the rate of malignancy in focal uptake were assessed. The SUV max of focal uptake was noted in patients with a focal thyroid incidentaloma and available final diagnosis.
Statistical Analysis
Statistical analysis was performed using commercially available software package SPSS version 16.0 (SPSS Inc., Chicago, Ill., USA). A Mann-Whitney U test was used to compare the SUV max of benign and malignant thyroid incidentalomas. Statistical significance was defined as p < 0.05. Receiver operating characteristic (ROC) analysis was performed to identify an SUV max cutoff in differentiating benign from malignant thyroid incidentalomas.
Results
Incidental focal uptake of tracer in the thyroid was observed in 147 patients. The final diagnosis was achieved in 47/147 (32%) by FNAC in 31 patients, histopathology of the surgical resection specimen in 10 and following neck USG in 6 patients ( table 1 ). In the rest of the patients, final cytological or histopathological diagnosis was not available due to several factors, such as further patient management in other hospitals, advanced primary malignancy with widespread metastatic disease, poor prognosis, low clinical index of suspicion or death. The final diagnosis showed benign lesions in 36 patients, papillary ( table 1 ) . In 2 patients, FNAC demonstrated indeterminate follicular lesions, but surgical excision was not performed. Thus, 9 out of 47 cases (19.1%) of thyroid focal uptake showed malignant involvement. In 5 patients with PTC, completion thyroidectomy histopathology results were available for 3 patients, which showed pT3N1 disease in 2 patients and pT1aN0 disease in 1 patient.
The mean SUV max of malignant focal thyroid uptake was 15.7 ± 5.9 and that of benign lesions was 7.1 ± 6.8. There was a highly significant difference between the SUV max in two groups (p = 0.000123; fig. 1 ). All patients with malignant thyroid pathology had a high SUV max of the focal uptake. Although most of the benign lesions showed low-grade tracer uptake, a high SUV max up to 39.0 was observed.
ROC analysis was performed to identify the cutoff SUV max for differentiating benign from malignant thyroid incidentalomas ( fig. 2 ) . The cutoff SUV max identified was 9.1 (sensitivity: 81.6%, specificity: 100%, area under the curve: 0.915). Further, serial 18 F-FDG PET studies were performed in 9 out of 47 patients, which showed a stable SUV max over 2-12 months in 5 patients with benign pathology. Two patients had new focal uptake in the thyroid when compared to the previous study, which was confirmed as lymphoma recurrence in one and a benign lesion in the other patient. Other two benign incidentalomas showed a variable trend in the SUV max . Figures 3-5 demonstrate focal thyroid uptake and its significance in a few cases from the study. 18 F-FDG is a glucose analogue and its mechanism of uptake is based on the higher glycolytic metabolism and the high expression of GLUT proteins in the malignant tissue [2] . The significance of incidental focal thyroid uptake on 18 F-FDG PET study was first described in 2001 [10] . Many research studies are currently available on this topic, with different results on focal uptake of tracer on 18 F-FDG PET [3-6, 8, 9, 11-38] ; however, a large UK series has yet to be reported. We report one of the largest studies on the evaluation of incidental focal 18 F-FDG uptake in the thyroid. The largest study by Bertagna et al. [4] included 49,519 patients, and focal thyroid uptake was identified in 1.5% of the patients. The authors reported that 34.1% of incidentalomas were malignant. Two studies with a large patient population by King et al. [26] and Kwak et al. [30] showed very low prevalence of focal in- 119 cidentalomas in 0.2 and 0.6% of the patients, respectively, similar to our study. However, the prevalence of thyroid incidentalomas on 18 F-FDG PET varies from 0.2 to 10.1% in different studies [4] . This could well be related to variation in geographic area, number of patients studied and patient characteristics.
Discussion
The incidence of malignant neoplasm in our cohort was 19.1% where a final diagnosis was available. Systematic review of previous studies on this topic by Soelberg et al. [39] showed malignancy in 34.8% of patients with focal uptake in the thyroid. However, our study showed a slightly lower incidence of malignant involvement of the thyroid in this population, similar to the King et al. [26] publication.
Previous studies have indicated that PTC and the follicular variant of PTC are the most prevalent thyroid cancer types, accounting for 81.1%, whereas lymphoma and secondary metastatic disease have been seen in only 4.1% of the patients [39] . Our study data is in concordance with previous findings showing PTC as the most frequent his- ] showed incidental focal uptake in a hypodense nodule in the left thyroid lobe (red arrows; colours refer to the online version only) with an SUV max of 5.0. In addition, intense uptake was noted in the right axillary lymph nodes (purple arrows; colours refer to the online version only). On histopathology, the left thyroid nodule was confirmed as a benign follicular adenoma. topathological type of primary thyroid cancer in these patients. Further, we did not find any other histopathological subtypes of the thyroid cancer. It has been mentioned previously that malignancy identified within the thyroid on 18 F-FDG PET may be more aggressive, which could be due to the fact that 18 F-FDG PET has less sensitivity in identifying differentiated cancers [5] . Interestingly, our results demonstrated that all incidentalomas with primary thyroid malignancies had differentiated PTC, with 1 patient having pT1a disease. FDG avid lesions are likely to be those that express GLUT1 intensely. There is some evidence that phosphatase and tensin homologue (PTEN)-negative PTC have considerable GLUT1 expression, and the relationship between the increasingly understood genetic alterations (BRAF, PTEN, etc.) and FDG avidity merits further study [40] . Furthermore, contradicting the previous findings, we found that almost half (44.4%) of the patients with malignant incidentaloma were due to secondary metastases or lymphoma.
The SUV assessed by 18 F-FDG PET/CT is a semiquantitative measure of glucose metabolism, which often reflects metabolic activity frequently correlated with biologic aggressiveness and clinical behaviour of malignant lesions, though not specific for malignancy. Literature evidence on the SUV max in benign and malignant lesions vary with several reports showing a statistically significant difference [9, 13, 19, 21-23, 34, 41] whilst many others have shown no significant difference [8, 14, 15, 27, 30, 32, 33, 35, 36] . Previous studies have also reported cutoff SUV values ranging from 3.5 to 5 in differentiated benign to malignant thyroid lesions [24, 34, 41] . In our study, a highly statistical difference was present between the SUV max of benign and malignant lesions. We found a cutoff value of 9.1 had 81.6% sensitivity and 100% specificity in differentiating benign from malignant lesions.
Considering the literature evidence and following the findings from our study, it may be suggested that in patients with an incidental focal thyroid uptake, an SUV max <3.3 and low clinical risk, one may be able to reassure the patients [42] . However, if there is a high clinical risk (such as previous history of radiation exposure and family history of thyroid cancer) or if the SU-V max is higher, the thyroid uptake should be regarded as suspicious for underlying malignancy and investigated further as appropriate. However, in patients with widespread metastases with poor prognosis, further investigation of incidental thyroid uptake may not be appropriate. The decision regarding investigating the incidental thyroid uptake needs to be made on an individual patient basis.
There are some limitations to our study which need to be mentioned. This being a retrospective study, a definitive diagnosis could not be available in many patients due to reasons such as further patient management in other hospitals, advanced primary malignancy with widespread metastatic disease, poor prognosis, low clinical index of suspicion or death. As data was collected over nearly 14 years, the studies were performed on different PET or PET/CT scanners. To our knowledge, however, this is the largest UK series on thyroid incidentalomas over the past 14 years. The results of this study are important as a lot of these findings were determined in a cohort of patients with poor prognosis or who may be terminally ill. It is also essential that patients with incidental focal thyroid uptake are properly evaluated and a collaborative protocol is established between referring clinicians, nuclear medicine physicians, endocrinologists and thyroid surgeons for the appropriate management of these patients. 
Conclusion
Incidence of focal thyroid uptake on 18 F-FDG PET study remains rare in our study cohort. The malignancy potential of these lesions, however, remains high and warrants prompt follow-up by the clinician. The SUV max may aid in further characterisation of the lesion and its management. Incidence of malignant primary and secondary pathology within these lesions remains equally possible.
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